News
Portfolio Company News
- November 15, 2012
AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain
- November 15, 2012
Threshold Pharmaceuticals Reports Updated Phase 2 Results Including Analyses of Maintenance Therapy With TH-302 Following Induction Therapy With TH-302 Plus Doxorubicin in Soft Tissue Sarcoma
- November 14, 2012
Trevena Completes FTIH Study of TRV130, an Injectable Mu-Opioid Biased Ligand for Acute Pain
- November 14, 2012
AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
- November 09, 2012
Ablynx to Present Rheumatoid Arthritis Data at
2012 American College of Rheumatology Annual Meeting
- November 06, 2012
Scynexis to Report Phase 2a Study of SCY-635 for Treatment of HCV at AASLD
- November 02, 2012
Aegerion Pharmaceuticals Announces Publication in The Lancet of Data From Its Pivotal Phase III Study of Lomitapide in Adult Patients with Homozygous Familial Hypercholesterolemia (HoFH)
- November 01, 2012
Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for its Novel, Dual Mechanism Compound, AR-13324, for the Treatment of Glaucoma
- November 01, 2012
Portola, Bristol-Myers Squibb and Pfizer Sign Clinical Collaboration Agreement to Study ELIQUIS® and Portola’s Universal Factor Xa Inhibitor Antidote PRT4445
- October 30, 2012
Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for a Fixed Combination of its Rho Kinase Inhibitor, AR-12286, with Travoprost for the Treatment of Glaucoma
- October 29, 2012
Cytokinetics Announces Opening of BENEFIT-ALS, A Phase IIb Clinical Trial of Tirasemtiv (CK-2017357) in Patients with Amyotrophic Lateral Sclerosis
- October 24, 2012
Astex Pharmaceuticals Announces Initiation of AT13387 Phase 2 Study in Non-Small Cell Lung Cancer
- October 23, 2012
SARcode Bioscience Announces Positive Topline Results from Phase 3 Dry Eye Study of Lifitegrast
- October 22, 2012
Bioventus Signs Lease for New Memphis Facility
- October 17, 2012
FDA Advisory Committee Recommends Approval of Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
- October 16, 2012
Threshold Pharmaceuticals Announces Agreement With U.S. FDA on a Special Protocol Assessment for Planned Phase 3 Trial of TH-302 in Combination With Gemcitabine in Advanced Pancreatic Cancer
- October 15, 2012
Astex Scientists Publish the Discovery of Novel Allosteric Modulators for the Key Therapeutic Targets HCV NS3 and PKM2 in Nature Journals
- October 08, 2012
Trevena Completes Phase 2a Study of TRV027 in Patients with Advanced Heart Failure
- October 05, 2012
Veloxis Pharmaceuticals A/S Announces Strategic Agreement for Chiesi Farmaceutici S.p.A. to Commercialize and Distribute Its Investigational Drug Candidate LCP-Tacro™ in Europe, Turkey and CIS Countries and Revised Outlook for 2012
- October 04, 2012
Ablynx Reports Excellent Interim Results from Phase I/II Study with its ANTI-IL-6R Nanobody, ALX-0061, in Rheumatoid Arthritis Patients
< Previous | Next >
